PRIME IL-15, the company’s lead investigational therapy, is a novel non-genetically modified, autologous, multiclonal T cell product derived from the patient’s T cell repertoire in the ...

MultiClonal Therapeutics Inc. (MCT) did not contribute to any primary research papers from Nature Index journals in the current 12 month window. Return to institution outputs Research leaders ...

MINNEAPOLIS, March 7, 2017 /PRNewswire/ -- Bio-Techne has entered into an exclusive license agreement with Multiclonal Therapeutics (MCT) to commercialize reagents and media systems in the ...